Charcot-Leyden crystals (CLCs) are Galectin-10 protein crystals that can form after eosinophils degranule. CLCs can appear and persist in tissues from patients with eosinophilic disorders, such as asthma, allergic reactions, fungal, and helminthic infections. Despite abundant reports of their occurrence in human disease, the inflammatory potential of CLCs has remained unknown. Here we show that CLCs induce IL-1β release upon their uptake by primary human macrophages in vitro, and that they induce inflammation in vivo in mouse models of acute peritonitis and bronchitis. CLC-induced IL-1β was dependent on NLRP3 and caspase-1, and their instillation in inflammasome reporter mice promoted the assembly of ASC complexes and IL-1β secretion in the lungs. Our findings reveal that CLCs are recognized by the NLRP3 inflammasome, which may sustain inflammation that follows eosinophilic inflammatory processes.
INTRODUCTION
Modifications in the physicochemical properties of certain proteins, lipids, or metabolites can result in phase transition leading to crystal formation or non-physiological aggregation (Franklin et al., 2016; Mulay and Anders, 2016) . Crystals can arise in tissues when endogenous material, such as minerals, cholesterol, and uric acid deposit. They can also be introduced from exogenous sources by inhalation (silica, asbestos, airborne particulate matter), or via injections (medical nanomaterials, vaccine adjuvants) (Franklin et al., 2016) .
Crystalline or aggregated materials are sensed by innate immune cells, which are equipped with germ-line encoded pattern recognition signaling receptors (PRRs). Innate immune cells survey tissues and remove accumulated extracellular material, pathogens, and residues of cellular demise. Sensing of crystals induces potent inflammatory responses, a property that has been exploited for adjuvanticity in vaccine formulations. Whereas several membranebound PRRs are involved in the recognition and uptake of crystals (Tsugita et al., 2017; Sheedy et al., 2013) , the cytosolic PRR NLRP3 senses excessively phagocytosed crystals.
NLRP3 activation causes the formation of an inflammasome that leads to activation and release of pro-inflammatory cytokine interleukin-1 beta (IL-1β) Duewell et al., 2010; Masters et al., 2010; Halle et al., 2008; Martinon et al., 2006b; Dostert et al., 2008) . IL-1β plays important roles in crystal-driven inflammatory diseases and, together with NLRP3, represents a promising therapeutic target for a range of crystal-mediated diseases (Franklin et al., 2016; Mulay and Anders, 2016) .
Inflammation occurs not only as a consequence of crystal buildup, but it can itself promote crystallization. During inflammation immune cells are recruited to the affected tissue. Among them, eosinophils and basophils play important roles in allergic reactions, fungal and helminthic infections, and in the regulation of a variety of autoimmune disorders.
These cells can expel highly cytotoxic proteins from their secretory granules, which mediate the marked physiological changes associated with eosinophil and basophil inflammation. A predominant protein present in eosinophilic and basophilic granules is Galectin-10 (LGASL10), also known as Charcot-leyden protein (Golightly et al., 1992; Archer and Blackwood, 1965) . Galectin-10 can cluster and form Charcot-Leyden Crystals (CLCs), which are colorless elongated hexagonal bipyramidal structures that can reach up to 50 μ m in length.
Since their first report, more than 160 years ago, CLCs have been shown to spontaneously form in vitro from lysates of eosinophils (Weller et al., 1980) and basophils (Ackerman et al., 1982) , and have been found to accumulate in tissues from patients with asthma (Dor et al., 1984) , fungal allergic reactions (el-Hashimi, 1971; Katzenstein et al., 1983; DeShazo et al., 1997) , helminthic infections (Kaplan et al., 2001) , and myeloid leukemia (Nashiro et al., 2016; van de Kerkhof et al., 2015; Manny and Ellis, 2012) . Despite abundant reports showing the appearance of CLCs in tissues from patients with eosinophilic disorders, these crystals are still regarded as inert remains of eosinophil activity, with unrecognized immune function.
Advances in this field have been hindered by the lack of a suitable animal model to study CLC formation in vivo. Mice lack the gene LGASL10, which encodes for Galectin-10.
Therefore, it remains to be demonstrated whether CLCs are inflammatory in vitro and in vivo.
Here we show that CLCs are promptly phagocytosed in vitro by human macrophages, and this leads to the release of the pro-inflammatory cytokine IL-1β. CLC-induced IL-1β in macrophages occurred through the activation of caspase-1 following the assembly of the NLRP3 inflammasome. Furthermore, we show that CLCs promoted inflammation in vivo, characterized by neutrophil infiltration, phagocytosis of the crystals, and IL-1β release.
Additionally, CLCs induced the assembly of inflammasomes (ASC specks) in vivo after their instillation into the lungs of ASC-mCitrine transgenic reporter mice.
Our findings uncover immune stimulatory features of CLCs and shed new light into the likely consequences caused by inflammatory sequelae that follow eosinophil infiltration in tissues.
RESULTS AND DISCUSSION

Production and characterization of Charcot-Leyden crystals
To investigate the inflammatory potential of CLCs, we first produced CLCs from whole cell lysates of AML14.3D10 cells, a subclone of the AML14 cell line that was established from a 68-year-old patient with FAB M2 acute myeloid leukemia (Baumann and Paul, 1998) . Both the parental AML14 cell line and the AML14.3D10 subclone are established tools for the study of eosinophil biology (Paul et al., 1994) . We produced CLCs in vitro by incubating pre-cleared lysates of AML14.3D10 cells at 4 o C for 16 hours (Fig. 1a, and Fig. S1a) as previously described (Ackerman et al., 1980) . The resulting crystals displayed the hexagonal bipyramidal morphology characteristic of CLCs (Fig. 1b) .
Coomassie Brilliant Blue staining of a gel loaded with SDS-denatured crystals revealed that CLC preparations contained mainly one protein (Fig. 1c, and Fig. S1a ), and immunoblotting with specific anti-Galecin-10 mAb showed that the CLC preparations were composed of Galectin-10 ( Fig. 1d and Fig. S1a ).
Phagocytosis of CLCs leads to IL-1β secretion by human macrophages
We next generated primary human monocyte-derived macrophages (hMDMs) differentiated from CD14 + monocytes isolated from the peripheral blood mononuclear cells (PBMCs) from buffy coats of healthy donors. These cells were primed with LPS and exposed to CLCs and their phagocytic potential against the CLCs was assessed by microscopy. We noticed that hMDMs promptly engulfed CLCs of variable sizes (Fig. 2a, and Movie S1).
The pro-inflammatory cytokine IL-1β is a key driver of crystal-induced inflammation in several chronic inflammatory diseases Duewell et al., 2010; Masters et al., 2010; Halle et al., 2008; Martinon et al., 2006b; Dostert et al., 2008) . We thus investigated whether phagocytosis of CLCs resulted in IL-1β release by hMDMs. We found that, similar to the well-established inflammasome activators silica and cholesterol crystals, exposure of LPS-primed hMDMs to CLCs resulted in a dose-and time-dependent release of IL-1β from these cells (Fig. 2b-c) . Similar to reports using other crystals, LPS priming was required for the release of IL-1β by in vitro CLC-stimulated hMDMs ( 
CLCs-induced IL-1β release in vitro depends on NLRP3 activation
Phagocytosis of crystalline material and insoluble protein aggregates can ultimately result in lysosomal damage and the release of lysosomal content into the cell cytosol.
Lysosomal damage can activate NLRP3, which then recruits the adapter protein ASC and caspase-1, a protein complex that enables maturation of pro-IL-1β by caspase-1-mediated proteolysis . To investigate whether lysosomal damage is involved in CLCs-induced inflammasome activation, we pre-treated hMDMs with CA-074 Me, a compound that inhibits lysosomal damage-mediated NLRP3 activation . Indeed, CA-074 Me inhibition blocked CLC-induced IL-1β release in a dosedependent manner (Fig. 2f) , suggesting that lysosomal damage is a likely mechanism by which CLCs can induce IL-1β secretion by macrophages. Inflammasome assembly can be visualized by ASC transition from a diffused cytosolic localization into a dot-like structure called the ASC speck (Stutz et al., 2013; Hoss et al., 2017) . We therefore performed immunofluorescence staining of ASC in LPS-primed hMDMs stimulated with CLCs. Using fluorochrome-conjugated anti-ASC antibodies, or isotype matched fluorochrome-conjugated IgGs, we revealed the formation of ASC specks in hMDMs that phagocytosed CLCs in vitro (Fig. 3a) .
In line with a role for the NLRP3 inflammasome in the intracellular sensing of CLCs, specific inhibition of NLRP3 and caspase-1 with the compounds CRID3 (Coll et al., 2015) and VX-765, respectively, ablated CLC-induced IL-1β release by hMDMs (Fig. 3b-c) . In contrast, the response to NAIP-NLRC4 inflammasome activation, tested through the delivery of the needle protein of the Salmonella pathogenicity island 1 type III secretion system (PrgI) into the cytosol, was not affected by the NLRP3 inhibitor CRID3, demonstrating specificity.
These findings indicate that, similar to silica , uric acid (Martinon et al., 2006a) , and cholesterol crystals (Duewell et al., 2010) , CLCs induce IL-1β activation and release from hMDMs by activating the NLRP3 inflammasome.
CLCs induce inflammasome activation in vivo
One of the main functions of IL-1 family cytokines is to induce the recruitment of immune cells, such as neutrophils and monocytes, which limits the spread of infection and initiates tissue repair (Dinarello, 2009) . Inflammasome activation in vivo is characterized by strong neutrophil infiltration in tissues (Satoh et al., 2013) , and tissue neutrophilia is a hallmark of IL-1-driven autoinflammatory diseases (Bonar et al., 2012; Broderick et al., 2015) . We therefore used a well-established mouse peritonitis model (Yanagida et al., 2013; Duewell et al., 2010; Hornung et al., 2008) to assess whether CLCs also promote neutrophil infiltration, which could indicate that inflammasomes are activated in vivo. We injected wildtype C57BL/6 mice intraperitoneally with PBS or with CLCs. Silica crystals were used as a positive control, as these crystals were reported to cause IL-1R-dependent neutrophil infiltration in vivo Kuroda et al., 2011) . Although peritoneal injection of CLCs is useful to assess crystal-induced inflammation in vivo, it does not represent a physiologically relevant site for CLC formation.
CLCs were frequently reported in the airways and sputum of patients with a variety of highly prevalent respiratory diseases, such as asthma (Dor et al., 1984) . To confirm whether CLCs induce inflammasome activation in vivo in the lung and to locally associate CLCs uptake with inflammasome activation, we performed intratracheal instillation of CLCs into the lungs of ASC-mCitrine transgenic reporter mice (Tzeng et al., 2016) . ASC-mCitrine mice were instilled with either PBS, CLCs, or silica crystals. Six hours after instillation, we assessed the infiltration of neutrophils, formation of mCitrine-fluorescent ASC specks, and production of pro-inflammatory cytokines in the bronchoalveolar lavage fluids (BALF). CLC-instilled mice displayed large numbers of neutrophils in their BALFs (Fig. 5a) . Very few or no neutrophils inflammasome-independent pro-inflammatory cytokine, were also elevated in the BALFs of mice treated with CLCs (Fig. 5c) .
Altogether, our data show that CLCs induce inflammasome activation in vivo and suggest that their accumulation in tissues might be an important driver for chronic tissue inflammation following eosinophil infiltration.
Concluding remarks
Our study identifies a previously unappreciated inflammatory capacity of CLCs and opens new avenues to consider the immunogenicity and potential relevance of these crystals for common chronic immunological diseases, such as asthma.
CLCs are found in the sputum of asthma patients with eosinophilia (Dor et al., 1984; Sakula, 1986) . Although asthma patients can display heterogeneous phenotypes, an important molecular mechanism of asthma is type 2 inflammation, which is characterized by an increase in IgE titers, the recruitment of eosinophils, and the predominance of T H 2 cells, which secrete IL-4, IL-5 and IL-13 (Fahy, 2015) . Type 2 immunity can also influence the expression of classical pro-inflammatory cytokines, such as IL-1β, that can assist in the development of chronic inflammation. In line with these observations, endogenous danger associated molecular patterns (DAMPs), including uric acid crystals, traditionally known as the cause of inflammation in gout, are strong adjuvants for Th2 immunity (Kool et al., 2008; .
Indeed, IL-1β levels have been shown to be increased in asthma, and the number of macrophages expressing IL-1β in the bronchial epithelium of asthma patients is higher in comparison with control subjects (Sousa et al., 1996) . Our findings show that CLCs, which are commonly found in fluids and tissues of patients with eosinophilia, induce strong release of the highly pro-inflammatory cytokine IL-1β. This finding, together with the report of CLCs found in the phagosomes of macrophages in vivo (Lao et al., 1998; Dvorak et al., 1990) ,
suggests that the uptake of CLCs by macrophages and the subsequent release of IL-1β can be one of the signals that perpetuate and exacerbate inflammation in the tissues of patients with eosinophilic disorders. On that note, IL-1β has been reported as a critical cytokine for the development of a Th2/Th17-predominant subtype in asthma patients (Liu et al., 2017) .
Th2/Th17-predominant asthma patients present dual-positive Th2/Th17 cells in their BALFs and exhibit a severe form of asthma. Moreover, these patients show increased eosinophil counts in their BALFs. Whether CLCs, which are a hallmark of eosinophilic diseases, are present in the BALFs of Th2/Th17-predominant asthma patients, and whether their recognition by alveolar macrophages are the cause of the increased levels of IL-1β in these patients is a matter of further research. In this scenario, inhibition of CLCs formation, engulfment, or effects in IL-1β release -potentially by blocking NLRP3 activity-could benefit patients with asthma.
The results presented in this study expand our current understanding on how protein crystallization contributes to immunogenicity and highlight the need to consider novel therapeutic strategies that neutralize protein crystallization lingering from the activity of granulocytes.
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Mice
Cell lines
The AML 14.3D10 cell line was kindly gifted from Meghan Sheehan, Cassandra C. Paul, and 
Human primary cells
Buffy coats from healthy donors were obtained according to protocols accepted by the institutional review board at the University of Bonn (local ethics votes Lfd. Nr. 075/14).
Primary human macrophages were obtained through differentiation of CD14+ monocytes in a medium complemented with 500 U/mL rhGM-CSF (Immunotools) for 3 days. In brief, human peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats of healthy donors by density gradient centrifugation in Ficoll-Paque PLUS (GE Healthcare).
PBMCs were incubated at 4 o C with magnetic microbeads conjugated to monoclonal antihuman CD14 antibodies (Miltenyi Biotec). CD14+ monocytes were thereby magnetically labeled and isolated using a MACS column placed in a magnetic field as indicated by manufacturer (Miltenyi Biotec). Monocytes-derived macrophages were cultivated in complete medium during all experiments.
Preparation of CLCs
CLCs were isolated following an adapted version of the protocol published elsewhere (Ackerman JI 1980) . All steps were carried out at 4 o C to avoid protein degradation and under sterile conditions using a class II biosafety cabinet and sterile reagents. At least 600 x10 Nuclei were stained with DRAQ5 (1:5,000, Thermo Fischer).
Microscopy
Confocal microscopy was combined with fluorescence microscopy using a Leica TCS SP5 SMD confocal system (Leica Microsystems, Wetzlar, Germany). Images were acquired using a 63X objective, with a numerical aperture of 1.2, and analysed using the Volocity 6.01 software (PerkinElmer, Waltham, Massachusetts, U.S.A.). For better visibility, in some instances, brightness and contrast were adjusted and all images within one experiment and applied equally to isotype controls and staining conditions.
In vivo peritoneal injection of CLCs
C57BL/6 mice were exposed to crystals by the peritoneal injection of 100 uL of PBS containing either 1 x10 6 CLCs, 100 μ g of silica crystals, or nothing. After 6 hours, mice were euthanized and 6 mL of lavage solution (RPMI + 3 mM EDTA) were injected into the peritoneum of mice as described elsewhere (Yanagida et al., 2013) . After massaging the distended peritoneal cavity, the peritoneal lavage fluid (PELF) was recovered and separated into a cellular fraction and a liquid fraction by centrifugation at 350 x g at 4 o C during 5 minutes. These cells were assayed in flow cytometry to determine neutrophil recruitment and also observed under the microscope (Leica SP5) to identify cells that have phagocytosed
CLCs.
Intratracheal instillation of crystals
C57BL/6 ASC-mCitrine mice were instilled at a dose of 1 mg of silica crystals, or 3.5 x 10 6 CLCs in 60 µL of PBS. The sample suspension was intratracheally instilled once to isoflurane anesthetized animals by a syringe through a catheter inserted into the airway. A control group was instilled with PBS alone. Mice were sacrified 6 hours after instillation, and 3 mL of bronchoalveolar lavage fluid was collected to determine the total cell count, neutrophil
) counts, and cytokine levels by HTRF.
Neutrophil recruitment assays
Cells recovered in the PELF or BALF were resuspended in 2 mL of staining solution (PBS + 
Cytokine levels measurement in the BALF
The liquid fraction of the BALF was concentrated using Amicon Ultra-2 mL 10K centrifugal filters. The amounts of mouse IL-1β and mouse TNF-α in the concentrated BALF were quantified using a HTRF assay kit (Cisbio Bioassays) and normalized to the volume of concentrated lavage.
Statistical analysis
Unless otherwise stated, all data is pooled from a minimum of 3 independent experiments carried out on macrophages from different donors. Table S1 : Source data for all the figure panels with human pooled IL-1β data from different donors. 
